← Back to patent-cliff list

Dactolisib

Tier C — Watch / trade

Dactolisib

Novartis
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:mTORC1, mTORC2, PI3Kβ, PI3Kα, PI3Kγ, PI3Kδ

Indications (approved):COVID-19, Respiratory tract infection, Breast cancer, 呼吸障碍, Solid tumour, Pancreatic neuroendocrine tumour, 肾肿瘤, Urothelial carcinoma

Regional status

US
Phase II
2011-10-01
EU
Discontinued
2012-01-30
China
-
Japan
Discontinued
2012-03-01

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 10 · Total yield /
DACT-001555-21-5DACT-00271825-51-9DACT-003115279-57-7DACT-004723281-72-9DACT-005915019-51-1DACT-006915019-52-2DACT-007915019-53-3DACT-008915019-50-0DACT-009191162-39-7DACT-0105794-88-7DACT-0111201643-75-5DACT-012853908-50-6API · Dactolisib
CodeCAS No.Intermediate
DACT-001555-21-52-(4-nitrophenyl)acetonitrile
DACT-00271825-51-92-methyl-2-(4-nitrophenyl)propanenitrile
DACT-003115279-57-72-(4-aminophenyl)-2-methylpropanenitrile
DACT-004723281-72-96-bromo-4-chloro-3-nitroquinoline
DACT-005915019-51-12-(4-((6-bromo-3-nitroquinolin-4-yl)amino)phenyl)-2-methylpropanenitrile
DACT-006915019-52-22-(4-((3-amino-6-bromoquinolin-4-yl)amino)phenyl)-2-methylpropanenitrile
DACT-007915019-53-32-(4-(8-bromo-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile
DACT-008915019-50-02-(4-(8-bromo-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile
DACT-009191162-39-7quinolin-3-ylboronic acid
DACT-0105794-88-72-amino-5-bromobenzoic acid
DACT-0111201643-75-5(E)-5-bromo-2-((2-nitrovinyl)amino)benzoic acid
DACT-012853908-50-66-bromo-3-nitroquinolin-4-ol

Frequently asked questions

What are the approved indications of Dactolisib?

Approved indications include: COVID-19, Respiratory tract infection, Breast cancer, 呼吸障碍, Solid tumour, Pancreatic neuroendocrine tumour, 肾肿瘤, Urothelial carcinoma.

When does the Dactolisib patent expire?

No public expiry year is available for Dactolisib yet; this page updates once verified.

How many synthesis routes are recorded for Dactolisib?

1 synthesis routes are recorded; the shortest is 10 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Dactolisib intermediates?

All intermediates in Dactolisib routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Dactolisib intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-19